公司概述
Modular Medical, Inc. operates within the healthcare sector, specifically focusing on the medical device industry, where it is dedicated to the design, development, and commercialization of insulin pumps for patients with type-1 and type-2 diabetes. The company's primary product offering includes MODD1, a two-part patch pump designed to address the specific needs of diabetic patients, distinguishing its operational scope within the broader medical technology landscape. As of the latest available data, the company maintains a market capitalization of $23.40M and employs a workforce of 53 individuals based in its headquarters in San Diego, California. These valuation and staffing metrics indicate that Modular Medical, Inc. functions as a micro-cap entity with a highly specialized product portfolio, suggesting a niche position in the competitive medical device market where capital efficiency is paramount for survival and expansion.
财务健康
Modular Medical, Inc. reports a net income of $-26,779,000 and an EBITDA of $-25,298,000 over the trailing twelve months, while annual revenue figures are not currently disclosed. The absence of reported revenue combined with significant net losses highlights a cost structure where operating expenses substantially exceed any generated sales, a common characteristic in early-stage device development but indicative of current financial strain. The company generates a free cash flow of $-15,671,375, which signifies a continuous consumption of cash reserves rather than the generation of liquidity, thereby limiting its immediate financial flexibility for strategic acquisitions or large-scale R&D investments. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a state where the company has not yet achieved profitability or where costs have fully eroded gross revenue in the financial reporting period. On the balance sheet, the company holds $2.94M in cash against $504,000 in debt, resulting in a debt-to-equity ratio of 8.57, which suggests a highly leveraged capital structure relative to its equity base despite the absolute value of debt being low. The current ratio stands at 1.59, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a baseline level of liquidity safety even amidst negative earnings. Furthermore, the return on equity is -331.8% and the return on assets is -149.8%, metrics that reveal management has struggled to generate positive returns on shareholder capital and the company's asset base over the trailing period.
估值评估
The valuation metrics for Modular Medical, Inc. present a complex picture with a forward P/E of -9.84 and a trailing P/E ratio listed as N/A due to negative earnings. The discrepancy between the negative forward P/E and the unavailable trailing P/E implies that analysts or market data providers are projecting continued earnings losses rather than an immediate turnaround to profitability. The price-to-book ratio is calculated at 2.21, indicating that the market values the company's equity at more than double its book value, which can suggest either high growth expectations or an overvaluation of its intangible assets and intellectual property in the current market environment. Alternative valuation measures such as the price-to-sales ratio are unavailable (N/A), while the EV/EBITDA stands at -0.42, further confirming that traditional earnings-based valuation multiples are not applicable and that the company is being valued primarily on asset or revenue multiples if available. The stock has exhibited extreme volatility, trading between a 52-week high of $34.50 and a 52-week low of $3.54, placing the current share price in a range that requires careful analysis of market sentiment given the wide spread. With a beta of -0.00, the stock displays a lack of correlation to broader market movements or exhibits statistical anomalies in its price data relative to market indices.
Growth & Income
Modular Medical, Inc. reports N/A for both revenue growth year-over-year and earnings growth year-over-year, preventing a direct comparison of whether earnings are growing faster or slower than revenue. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead reinvests its limited resources into product development and operational scaling. The absence of a dividend program aligns with the company's status as a growth-oriented entity that prioritizes funding its insulin pump operations over returning capital to investors. The overall growth and income profile is characterized by a complete lack of historical earnings growth data and zero dividend income, reflecting the high-risk, high-reward nature of a pre-profitability medical device company operating with significant cash burn.